Tango Therapeutics, Inc.
Here’s whether Tango Therapeutics, Inc. (TNGX) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Neutral.
Positives: trading above the 200-day MA (long-term uptrend intact); 50-day MA is rising (+4.22% over 10 days); RSI 38 — healthy momentum range; strong 1-year return of +294.5%. Concerns: below the 50-day MA (medium-term momentum negative); declining volume on rally — weak conviction (0.49x 30d avg). Currently 22.6% off its 52-week high. Score: +3/7.
TNGX is holding above its long-term 200-day MA ($16.98) but has slipped below the 50-day MA ($26.95), pointing to short-term weakness in an otherwise intact trend. An RSI of 38.5 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +294.5% compares to +16.5% for SPY (beat the market by 278.1%). The current 22.6% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.